Actively Recruiting
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Led by University of Texas Southwestern Medical Center · Updated on 2026-03-16
112
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.
CONDITIONS
Official Title
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-65 years old
- No symptoms of viral infection at study entry
- High-risk exposure without masks to a confirmed COVID-19 case
- Living in a household with a confirmed COVID-19 case
- Negative baseline SARS-CoV-2 diagnostic test
You will not qualify if you...
- Women with hormonal variations affecting immune function (including transgender, pregnant, breastfeeding)
- Significant clinical diseases such as cardiovascular disease, heart disease, lung disease, kidney disease (GFR < 60 ml/min/1.73 m2), liver disease, or major immunosuppression
- History of gastrointestinal disease that may cause nausea
- History of autoimmune diseases
- Chronic viral hepatitis
- Use of systemic immunomodulatory medications within 4 weeks of enrollment
- Receipt of investigational drugs within 30 days prior to dosing
- History of cardiac arrhythmia or recent severe cardiac or pulmonary events
- Allergy to study drug components or similar compounds including Coenzyme Q10 and idebenone
- Unable to swallow tablets
- Use of investigational products within 4 weeks of enrollment
- Any condition or therapy making participation unsuitable or compliance unlikely
- Eligible for other FDA-approved post-exposure prophylaxis treatments for SARS-CoV-2
- Use of Coenzyme Q10 or Vitamin E within 120 days prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75219
Actively Recruiting
Research Team
T
Theodoros Kelesidis, MD, PHD, Msc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here